Danielle Gipson, a senior at LSU, has spent the past two years conducting independent research on triple-negative breast cancer.
Gipson has developed a new therapy using fiestien, which prevents tumor growth in cancer cells. Her approach is unique because it also involves a genetically engineered herpes virus that targets cancer cells while leaving healthy tissue unharmed.
Gipson’s research is personally motivated. Her great aunt passed away a few years ago, inspiring her to pursue cancer research.
“After she passed away, almost two years into me being in college, I decided to pursue cancer research,” Gipson said. “I’ve always been interested in women’s health, and pursuing cancer research would be a way for me to continue her legacy.”
Her work extends beyond the lab. Gipson has also researched the social factors that impact those affected by triple-negative breast cancer. Her findings show that Black women are more likely to be diagnosed with breast cancer, and that people under 40 are also at greater risk.
Gipson’s comprehensive approach to research addresses multiple facets of the disease, considering both scientific and social elements.
Last month, LSU recognized Gipson for her impressive work. She and her team have worked tirelessly in hopes of finding a solution to this deadly disease. Gipson will graduate in May and plans to take a gap year while applying to medical schools.
“I love research, and I definitely want to return to it,” Gipson said. “But I’m excited for what’s next as I begin my medical journey.”
Through her innovative research and dedication, Gipson has made significant progress in developing a new therapy for breast cancer, offering hope for more effective treatments and improved outcomes for patients.